NCT01397734终止1 期
Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Number of Participants with Adverse Events as a Measure of Safety and Toxicity
研究概览
简要总结
In this research study, the investigators are looking to see whether the combination of arsenic trioxide with a tyrosine kinase inhibitor is safe, and what effects it has on chronic myelogenous leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have a diagnosis of chronic myelogenous leukemia as confirmed by fluorescent In Situ Hybridization (FISH) for BCR/ABL translocation and/or standard cytogenetics analysis.
- •Participants may have received prior hydroxyurea but may not be currently being treated with hydroxyurea at the time of study initiation.
- •Participants may have received prior TKI therapy, however must be on a stable dose of their current TKI for at least one month prior to enrollment.
- •Participants must demonstrate evidence of persistent disease either by cytogenetics/FISH or by PCR for BCR/ABL in the peripheral blood or bone marrow.
- •Greater than or equal to 18 years in age. Because little dosing or adverse event data are currently available on the use of Arsenic in participants <18 years of age, children are excluded from this study.
- •Life expectancy of greater than 3 months
- •ECOG performance status <2
- •Participants must have normal organ and marrow function as defined below:
- •Bilirubin ≤ 2.0 mg/dL
- •Creatinine ≤ 2 mg/dL
- •ALT < 2.5 X institutional upper limit of normal
- •AST < 2.5 X institutional upper limit of normal
- •WBC > 2.0 K/uL
- •Platelets >100K
- •Oxygen saturation > 95% on room air
- •The effects of Arsenic on the developing human fetus are unknown. For this reason, women of child-bearing potential must have a documented negative pregnancy test; in addition, agreement to use adequate contraception (hormonal or barrier method of birth control; abstinence) must be documented for both women of child-bearing potential and men prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- •All patients must demonstrate the ability to understand the investigational nature of this study and must sign a written informed consent document in accordance with institutional and federal guidelines
排除标准
- •History of acute myocardial infarction, unstable angina, congestive heart failure, or arrhythmia within the last three months
- •Participants may not be receiving any other study agent
- •Mean QTc> 450 ms at time of screening
- •Use of potassium wasting diuretics during study treatment
- •Patients should not be taking drugs that are generally accepted to have a risk of causing Torsades de Pointes. The following must be discontinued at least 7 days prior to enrollment to be eligible: quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
- •Drugs that are highly dependent on CYP3A4 for metabolism and have a narrow therapeutic index (see Appendix A) are allowed but must be used with caution
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Concurrent and or uncontrolled psychiatric or medical condition which may interfere with the study completion.
- •Pregnant women are excluded from this study because the risk of Arsenic to a developing fetus is unknown. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with Arsenic, breastfeeding should be discontinued if the mother is treated on this clinical trial
- •Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
- •HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with TKI therapy and Arsenic. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy.
研究组 & 干预措施
Cohort 1
Experimental
Patients who are receiving Imatinib as part of their standard of care therapy for CML.
干预措施: Arsenic trioxide (Drug)
Cohort 2
Experimental
Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
干预措施: Arsenic trioxide (Drug)
Cohort 3
Experimental
Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
干预措施: Arsenic trioxide (Drug)
结局指标
主要结局
Number of Participants with Adverse Events as a Measure of Safety and Toxicity
时间窗: 1, 2, 6, 12 months
To assess the safety and toxicity of arsenic in combination with TKI therapy for chronic phase CML patients
次要结局
- PML Expression(1, 6, 12 months)
- Disease Response(1, 2, 6, 12 months)
研究者
David Avigan, MD
Prinicipal Investigator
Beth Israel Deaconess Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
All-trans Retinoic Acid, and Arsenic +/- IdarubicinAcute Promyelocytic LeukemiaNCT00413166M.D. Anderson Cancer Center78
Unknown
1 期
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid AcidAcute Myeloid LeukemiaNCT05297123First Affiliated Hospital Xi'an Jiaotong University30
终止
2 期
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous LeukemiaAcute Myelogenous LeukemiaNCT00184054University of Southern California11
已完成
2 期
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic SyndromesMyelodysplastic SyndromesLeukemiaNCT00274781The Cleveland Clinic30
已完成
2 期
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT00193518SCRI Development Innovations, LLC41